Hemispherx BioPharma’s board of directors voted this week to terminate the employment of its long-time CEO Dr. William A. Carter, according to documents filed with the Securities and Exchange Commission.
Carter, 77, has been at the helm of the Philadelphia company for more than two than decades as it sought, unsuccessfully, to secure regulatory approval for a lead drug candidate called Ampligen. Ampligen, a specifically-configured ribonucleic acid compound co-invented by Carter, has been studied…Hemispherx BioPharma’s board of directors voted this week to terminate the employment of its long-time CEO Dr. William A. Carter, according to documents filed with the Securities and Exchange Commission.
Carter, 77, has been at the helm of the Philadelphia company for more than two than decades as it sought, unsuccessfully, to secure regulatory approval for a lead drug candidate called Ampligen. Ampligen, a specifically-configured ribonucleic acid compound co-invented by Carter, has been studied…